Integra LifeSciences price target lowered to $65 from $75 at JMP Securities

JMP Securities analyst David Turkaly lowered the firm’s price target on Integra LifeSciences to $65 from $75 and keeps an Outperform rating on the shares. Quarterly sales were slightly above the high end of the guidance range, while adjusted EPS was about in line with the midpoint, and management reiterated its annual guidance ranges on both the top and bottom lines, but also provided additional commentary around why 1H23 will be a bit softer than the back half of the year, the analyst tells investors in a research note.